AstraZeneca Vietnam cooperates to distribute pharmaceutical products in the cancer industry

Speaking at the signing ceremony, Master, Pharmacist Le Ngoc Danh, Head of the Department of Pharmacy, Ho Chi Minh City Department of Health , emphasized that reducing the burden of disease and death due to cancer is always one of the top priorities of the health sector. In which, screening, early detection and highly effective treatment with advanced therapies are extremely important.

The cooperation between AstraZeneca Vietnam and Hoang Duc Company helps Vietnamese patients have early access to new drugs in the world, bringing important benefits to patients and the community.

AstraZeneca Việt Nam hợp tác phân phối dược phẩm ngành hàng ung thư - Ảnh 1.

AstraZeneca Vietnam announces distribution partner for oncology pharmaceuticals in Vietnam

Mr. Nitin Kapoor, Chairman and General Director of AstraZeneca Vietnam Company Limited said: "AstraZeneca is very proud to accompany the development of Vietnam's healthcare industry for nearly 30 years. The signing ceremony is a testament to our continued commitment to continue improving access to medicines for patients in Vietnam, better meeting the healthcare needs of the people, and building sustainable value for patients and society."

In addition to improving patients’ access to advanced medicines, this cooperation will also contribute to enhancing the capacity of domestic pharmaceutical distribution enterprises, strengthening the sustainability of the pharmaceutical supply chain, thereby contributing to the comprehensive development of the Vietnamese pharmaceutical industry.

Present in Vietnam for nearly 3 decades, with nearly 600 employees nationwide, AstraZeneca has been collaborating with the Ministry of Health and industry partners to implement many influential programs to promote awareness, prevention and early detection of diseases. A typical example is the "For Healthy Lungs" program to improve the quality of outpatient management for asthma, COPD (chronic obstructive pulmonary disease) and lung cancer...

Source